Osteonecrosis of the Jaw in a Patient With Advanced Non-Small-Cell Lung Cancer Receiving Bevacizumab;Osteonecrosis mandibular en un paciente con cáncer de pulmón no microcítico avanzado tratado con bevacizumab

Archivos de Bronconeumologia

Volumn 48, Issue 6, 2012, Pages 218-219

  Katsenos, Stamatis ^a   Christophylakis, Charalampos ^a   Psathakis, Konstantinos ^a  

^a KAT HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB;

ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; HUMAN; JAW OSTEONECROSIS; LETTER; LUNG NON SMALL CELL CANCER;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; BISPHOSPHONATE-ASSOCIATED OSTEONECROSIS OF THE JAW; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED;

EID: 84860691168     PISSN: 03002896     EISSN: 15792129     Source Type: Journal    
DOI: 10.1016/j.arbres.2012.01.007     Document Type: Letter

References (5)

1. Migliorati C.A., Epstein J.B., Abt E., Berenson J.R. Osteonecrosis of the jaw and bisphosphonates in cancer: a narrative review. Nat Rev Endocrinol 2011, 7:34-42.
2. Van Poznak C. Osteonecrosis of the jaw and bevacizumab therapy. Breast Cancer Res Treat 2010, 122:189-191.
3. Estilo C.C., Fornier M., Farooki A., Carlson D., Bohle G., Huryn J.M. Osteonecrosis of the jaw related to bevacizumab. J Clin Oncol 2008, 26:4037-4038.
4. Christodoulou C., Pervena A., Klouvas G., Galani E., Falagas M.E., Tsakalos G., et al. Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone. Oncology 2009, 76:209-211.
5. 3) delivered in oil suspension applications for the treatment of osteonecrosis of the jaw in patients with bone metastases treated with bisphosphonates: preliminary results of a phase I-II study. Oral Oncol 2011, 47:185-190.